# OnCo record paper-pembrolizumab-urothelial-n-engl-j-med-2017 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-pembrolizumab-urothelial-n-engl-j-med-2017/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-pembrolizumab-urothelial-n-engl-j-med-2017" ;
  schema:name "Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma"@en ;
  schema:description "Phase 2 or 3 results paper on Pembrolizumab in Bladder & urothelial cancer, in New England Journal of Medicine (2017), one of the most cited Europe PMC records with Pembrolizumab in its title."@en ;
  schema:url <https://onco.cc/key-papers/paper-pembrolizumab-urothelial-n-engl-j-med-2017/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/nejmoa1613683>, <https://pubmed.ncbi.nlm.nih.gov/28212060/>, <https://europepmc.org/article/MED/28212060> ;
  onco:tag "europepmc-ingest" ;
  schema:sameAs <https://doi.org/10.1056/nejmoa1613683> ;
  schema:datePublished "2017"^^xsd:gYear ;
  schema:author "Bellmunt J, de Wit R, Vaughn DJ, et al." ;
  onco:journals <https://onco.cc/journals/nejm/> .